Obe-cel Shows Complete Remissions up to 3 Years in R/R B-ALL


A pooled analysis of the ALLCAR19 and FELIX trials including patients with R/R B-ALL, B-CLL, and B-NHL were presented at ASH 2023.

Obecabtagene autoleucel (obe-cel) CD19-targeted chimeric antigen receptor (CAR) T cell therapy has demonstrated over 3 years of safety and efficacy in patients with relapsed/refractory B-cell acute lymphocytic leukemia (R/R B-ALL).

Updated data from a pooled analysis of the phase 1 ALLCAR19 trial (NCT02935257) and the phase 1b/2 FELIX trial (NCT04404660) were presented by Claire Roddie, MD, PhD, FRCPath, MBChB, MRCP, associate professor, haemato-oncology, University College London, at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California.

“Obe-cel is an autologous CAR T-cell product designed to reduce toxicity and improve persistence through a fast off-rate CD19 binding domain.Additionally, obe-cel has been tested in patients with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell non-Hodgkin lymphoma (B-NHL),” Roddie and colleagues wrote in the abstract.

ALLCAR19 is a multicenter, open-label phase 1 trial in patients aged at least 16 years, originally limited to R/R B-ALL but then amended to include patients with R/R B-CLL and NHL in an extension study. FELIX is a global, single-arm Phase Ib/II study enrolling adult patients with R/R B-ALL. Obe-cel was administered as a split dose in patients with B-ALL (target dose of 410 × 106 CAR T cells) andCLL (target dose 230 × 106 CAR T cells), and as a single infusion in patients with B-NHL (target dose 200 × 106 CAR T cells). Patient populations were similar between studies and patients with B-ALL are continuing to be followed for disease progression and survival.

The new data in B-ALL are from 20 patients in ALLCAR19 (data cutoff June 2023) and 16 in FELIX (data cutoff March 2023). The median age was 41.5 years (range, 18-74) and the median lines of prior therapy was 3 (range, 2-6). Twenty-nine patients (81%) achieved complete remission (CR) with incomplete hematologic recovery per investigator assessment. Event-free survival rate was 64% at 6 months and 49% at 12 months. Patients had a median of 43 months (range, 19-62) of follow up and 13 of 36 responders (36%) remain in remission (8 from ALLCAR19 and 5 from FELIX) with minimal residual disease negativity. Two of these ongoing responders had consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT)and 10 who did not still had detectable CAR T cells at the last follow up.The estimated 2-, 3- and 4-year overall survival rates were 44%, 39% and 39%, respectively.

Looking at patients with R/R B-CLL and B-NHL, 26 treated patients (5 with B-CLL and 21 with B-NHL) had a median age of 61 years (range, 39-79) and a median 3 prior lines of treatment (range, 2-8). Overall response rate was 92% (n = 24) at a median follow up of 24 months and 58% (n = 14) were alive without disease progression at the last follow up.

In terms of safety, 10 of the ongoing B-ALL responders that did not receive allo-HSCT had ongoing B-cell aplasia. Of the 14 ongoing responders with B-CLL/NHl, 12 have ongoing B-cell aplasia. These cases did not correlate with an increased risk of late serious infection and no other long-term toxicties related to obe-cel were reported.

“The combined analysis of data from the ALLCAR19 and FELIX Phase Ib studies shows long-term efficacy and safety of obe-cel in pts with R/R B-ALL, with approximately one-third of pts still in remission without consolidative allo-HSCT after a median follow up of >3 years. Durable responses of >2 years were also seen in pts with R/R B-CLL and R/R B-NHL.B-cell aplasia was commonly found in long-term follow up of obe-cel recipients, but without a corresponding rise in serious late infections. Obe-cel can effect durable long-term remissions in B-cell malignancies,” Roddie and colleagues concluded.

Click here to read more coverage of the ASH 2023 meeting.

Roddie C, Tholouli E, Shaughnessy P, et al. Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study). Presented at: 2023 ASH Annual Meeting & Exposition, December 9-12; San Diego, California. Abstract 2114.
Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration
© 2024 MJH Life Sciences

All rights reserved.